SHANGHAI, China and CUPERTINO, CA, USA I October 03, 2018 I Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a Patent License Agreement (the “License Agreement”) with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services. Pursuant to the License Agreement, NCI granted CBMG a non-exclusive, sub-licensable worldwide license to develop, manufacture and commercialize next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology to treat a variety of cancers.
“We are extremely pleased to finalize this License Agreement as this next generation TIL technology will fortify our clinical development pipelines for solid tumors. It is a significant extension of our CAR/TCR-T pipelines against solid tumors in the immuno-oncology platform,” stated Tony (Bizuo) Liu, Chief Executive Officer of CBMG. “The medical oncology community is very aware of the innovative work using T cell-based immunotherapy and autologous TIL transfer for the treatment of various cancers. We look forward to continuing to advance this field.”
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Our Shanghai facility includes a ”Joint Laboratory of Cell Therapy” with GE Healthcare and a “Joint Cell Therapy Technology Innovation and Application Center” with Thermo Fisher Scientific, whose partnerships focus on improving manufacturing processes for cell therapies. The CBMG pipeline includes preclinical compounds targeting CD20-, CD22- and B-cell maturation antigen (BCMA)-specific CAR-T compounds, and T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) technologies. A Phase IIb trial in China for Rejoin® autologous Human Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial in China for AlloJoin™ (CBMG’s “Off-the-Shelf” haMPC) for the treatment of KOA are ongoing. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.
SOURCE: Cellular Biomedicine Group
Post Views: 173
SHANGHAI, China and CUPERTINO, CA, USA I October 03, 2018 I Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a Patent License Agreement (the “License Agreement”) with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services. Pursuant to the License Agreement, NCI granted CBMG a non-exclusive, sub-licensable worldwide license to develop, manufacture and commercialize next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology to treat a variety of cancers.
“We are extremely pleased to finalize this License Agreement as this next generation TIL technology will fortify our clinical development pipelines for solid tumors. It is a significant extension of our CAR/TCR-T pipelines against solid tumors in the immuno-oncology platform,” stated Tony (Bizuo) Liu, Chief Executive Officer of CBMG. “The medical oncology community is very aware of the innovative work using T cell-based immunotherapy and autologous TIL transfer for the treatment of various cancers. We look forward to continuing to advance this field.”
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Our Shanghai facility includes a ”Joint Laboratory of Cell Therapy” with GE Healthcare and a “Joint Cell Therapy Technology Innovation and Application Center” with Thermo Fisher Scientific, whose partnerships focus on improving manufacturing processes for cell therapies. The CBMG pipeline includes preclinical compounds targeting CD20-, CD22- and B-cell maturation antigen (BCMA)-specific CAR-T compounds, and T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) technologies. A Phase IIb trial in China for Rejoin® autologous Human Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial in China for AlloJoin™ (CBMG’s “Off-the-Shelf” haMPC) for the treatment of KOA are ongoing. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.
SOURCE: Cellular Biomedicine Group
Post Views: 173
